SCHEMBL4090933

SCHEMBL4090933

CCOC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CC(C)(C)NC2(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.66
MEN1 O00255 4/20 0.66
ALDH1A1 P00352 4/20 0.66
KDM4E B2RXH2 3/20 0.66
LMNA P02545 3/20 0.66
THRB P10828 1/20 0.66
UBE2N P61088 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TP53 P04637 1/20 0.53
RPS6KB1 P23443 1/20 0.51
CDK2 P24941 1/20 0.51
MAPKAPK2 P49137 1/20 0.51
GSK3B P49841 1/20 0.51
RPS6KA3 P51812 1/20 0.51
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 2/20 0.49
GLA P06280 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18300329 0.83 KMT2A (0.64) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18300097 0.79 KMT2A (0.61) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18309615 0.78 ALDH1A1 (0.68) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL8290355 0.78 KMT2A (1.00) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18300584 0.78 ALDH1A1 (0.68) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18300711 0.78 KMT2A (0.65) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL3740600 0.78 KMT2A (0.57) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18309614 0.78 ALDH1A1 (0.67) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL18300523 0.76 LMNA (0.61) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL14233157 0.76 LMNA (0.68) KMT2AMEN1ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 KMT2A 2505/4885MEN1 3065/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.